VKTX Viking Therapeutics Inc

Price (delayed)

$29.82

Market cap

$3.46B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.15

Enterprise value

$3.34B

?
Relative Growth: Rel. Growth: 0
Relative Strength: Rel. Strength: 41
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 1

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and ...

Highlights
Viking Therapeutics's debt has shrunk by 100% QoQ and by 100% YoY
The company's quick ratio has shrunk by 87% YoY and by 38% QoQ
VKTX's equity is down by 41% year-on-year and by 21% since the previous quarter

Key stats

What are the main financial stats of VKTX

VKTX stock price

How has the Viking Therapeutics stock price performed over time
Intraday
1.67%
1 week
-7.36%
1 month
-6.11%
1 year
10.44%
YTD
-15.24%
QTD
-8.36%

Financial performance

How have Viking Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$502M
Net income
-$472.34M
Gross margin
N/A
Net margin
N/A
Viking Therapeutics's operating income has plunged by 191% YoY and by 28% from the previous quarter
The net income fell by 31% QoQ

Price vs fundamentals

How does VKTX's price correlate with its fundamentals

Growth

What is Viking Therapeutics's growth rate over time

Valuation

What is Viking Therapeutics stock price valuation
P/E
N/A
P/B
6.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 30% since the previous quarter
The P/B is 50% more than the 5-year quarterly average of 4.5 and 25% more than the last 4 quarters average of 5.4
VKTX's equity is down by 41% year-on-year and by 21% since the previous quarter

Efficiency

How efficient is Viking Therapeutics business performance
The ROIC has dropped by 56% since the previous quarter
Viking Therapeutics's ROE has decreased by 49% from the previous quarter
VKTX's ROA is down by 43% since the previous quarter

Dividends

What is VKTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VKTX.

Financial health

How did Viking Therapeutics financials performed over time
VKTX's current ratio has dropped by 87% year-on-year and by 39% since the previous quarter
The company's quick ratio has shrunk by 87% YoY and by 38% QoQ
Viking Therapeutics's debt is 100% lower than its equity
Viking Therapeutics's debt has shrunk by 100% QoQ and by 100% YoY
VKTX's equity is down by 41% year-on-year and by 21% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.